Emergent BioSolutions Inc. (NYSE:EBS) Stake Lessened by Texas Permanent School Fund

Texas Permanent School Fund trimmed its position in shares of Emergent BioSolutions Inc. (NYSE:EBSGet Rating) by 6.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,850 shares of the biopharmaceutical company’s stock after selling 2,070 shares during the period. Texas Permanent School Fund owned approximately 0.06% of Emergent BioSolutions worth $353,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Covestor Ltd increased its position in Emergent BioSolutions by 43.8% in the 1st quarter. Covestor Ltd now owns 1,612 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 491 shares during the period. Baird Financial Group Inc. increased its holdings in Emergent BioSolutions by 9.1% during the 1st quarter. Baird Financial Group Inc. now owns 7,313 shares of the biopharmaceutical company’s stock worth $300,000 after acquiring an additional 607 shares during the period. Centaurus Financial Inc. boosted its stake in shares of Emergent BioSolutions by 19.6% in the 1st quarter. Centaurus Financial Inc. now owns 3,796 shares of the biopharmaceutical company’s stock valued at $156,000 after purchasing an additional 621 shares in the last quarter. Guggenheim Capital LLC boosted its position in Emergent BioSolutions by 0.8% during the 1st quarter. Guggenheim Capital LLC now owns 85,792 shares of the biopharmaceutical company’s stock valued at $3,522,000 after buying an additional 680 shares during the period. Finally, Ancora Advisors LLC purchased a new stake in Emergent BioSolutions during the 1st quarter valued at $66,000. Institutional investors own 80.44% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. TheStreet downgraded shares of Emergent BioSolutions from a “c-” rating to a “d” rating in a report on Monday, February 27th. StockNews.com initiated coverage on shares of Emergent BioSolutions in a research note on Thursday. They issued a “sell” rating for the company. JPMorgan Chase & Co. reiterated an “underweight” rating and issued a $9.00 target price (down from $23.00) on shares of Emergent BioSolutions in a report on Friday, March 17th. Finally, Benchmark upgraded shares of Emergent BioSolutions from a “hold” rating to a “buy” rating and set a $22.00 price objective on the stock in a report on Monday, April 10th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $28.00.

Emergent BioSolutions Stock Down 4.4 %

Emergent BioSolutions stock opened at $8.64 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.70 and a current ratio of 1.00. The firm has a market capitalization of $435.87 million, a price-to-earnings ratio of -1.07 and a beta of 0.93. Emergent BioSolutions Inc. has a fifty-two week low of $7.74 and a fifty-two week high of $40.45. The stock’s fifty day moving average is $9.71 and its two-hundred day moving average is $12.03.

Emergent BioSolutions (NYSE:EBSGet Rating) last issued its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($3.17) EPS for the quarter, missing the consensus estimate of ($1.67) by ($1.50). The firm had revenue of $165.10 million during the quarter, compared to analyst estimates of $142.85 million. Emergent BioSolutions had a negative return on equity of 20.18% and a negative net margin of 41.20%. Emergent BioSolutions’s revenue was down 46.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.18 EPS. Analysts predict that Emergent BioSolutions Inc. will post -1.29 EPS for the current fiscal year.

Emergent BioSolutions Company Profile

(Get Rating)

Emergent BioSolutions Inc engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm’s products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV.

Featured Stories

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent BioSolutions Inc. (NYSE:EBSGet Rating).

Institutional Ownership by Quarter for Emergent BioSolutions (NYSE:EBS)

Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.